Metagenomi Therapeutics (MGX) Shares Outstanding (Weighted Average) (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Shares Outstanding (Weighted Average) data on file, last reported at $37.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $37.6 million, up 1.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.6 million (up 1.52% YoY), and the FY2025 annual result was $37.3 million, up 12.79% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $37.6 million in Q1 2026 per MGX's latest filing, from $37.3 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $37.6 million in Q1 2026 and troughed at $3.4 million in Q1 2023.
• A 4-year average of $24.8 million and a median of $33.0 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) soared 975.76% in 2024, then grew 1.45% in 2025.
• A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $3.4 million in 2023, then surged by 870.1% to $33.0 million in 2024, then climbed by 12.79% to $37.3 million in 2025, then advanced by 0.89% to $37.6 million in 2026.
• Business Quant data shows MGX's Shares Outstanding (Weighted Average) at $37.6 million in Q1 2026, $37.3 million in Q4 2025, and $37.2 million in Q3 2025.